Exponent (EXPO) Q3 2026 earnings review
Exponent lifts its annual plan, while its environmental unit slows
Exponent, a scientific and engineering consulting firm, beat its own third-quarter targets and raised its full-year plan, while its smaller environmental unit slowed down. Revenue before pass-through costs grew 12% as consultant billable hours reached 77% of available time. Chief executive Catherine Corrigan pointed to user research and product-failure disputes, though the fourth-quarter outlook calls for growth to ease to 9%.
| Revenue before reimbursements | $153.1M +11.7% from a year ago (8–10% plan) |
|---|---|
| EBITDA margin (of net revenue) | 29.4% +1.1 percentage points from a year ago |
| Consultant utilization rate | 77% 74% last quarter (74–75% plan) |
| Full-year net revenue outlook | Raised 1 pt middle of the range: 10.5% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because demand held up even as a single huge user-research project was supposed to shrink by half, and a pause in stock buybacks let cash rebound by $48 million to $115 million. One caution: the environmental and health division slowed back to 3% growth, leaving the company reliant on its engineering practice.
The question now is whether the fourth-quarter slowdown in the outlook is routine caution or a sign that electronics testing is cooling off. One camp sees a growing list of artificial intelligence hardware projects across industries, while skeptics see heavy reliance on a few big tech contracts. The single-client revenue disclosure in the third-quarter filing will settle it.
🐂 Bull Case
User Research Kept Growing as Big Project Slowed
"User research studies continued to be a strong contributor to our growth, as clients move quickly to understand how people interact with technology across a widening range of devices and applications," chief executive Catherine Corrigan said. In these studies, Exponent tests how real people use new hardware and software. Skeptics worried that this work relied on one consumer electronics client that made up 11% of second-quarter revenue, and on a single study that management expected to shrink by half.
The engineering and scientific division, which makes up 85% of revenue before reimbursements, grew 13% from a year ago. Pass-through reimbursable costs, which come mostly from paying participants in user research studies, stayed more than double last year's level at $20.7 million and dipped only 9% from the second quarter. The division also expanded into "health applications, dynamic and unstructured real-world environments, and sensory perception", while Corrigan noted "increased dispute-related and failure analysis demand in the chemical, consumer products and transportation industries".
Because pass-through study costs barely fell when the single large project was supposed to halve, other clients and projects filled the gap. That argues the user research practice is broadening across industries rather than resting on one electronics contract.
What to watch: the single-client revenue share in the third-quarter filing's footnote. A reading below 10% would confirm that user research growth is spreading across multiple clients.
Higher Staff Billable Hours Lifted Profit Margins
"Our ability to scale our operating model in response to market demand resulted in 77% utilization and expanded profitability during the third quarter of 2026," finance chief Eric Anderson said. Utilization measures the share of consultants' time billed to clients, and management had forecast 74% to 75% for the quarter.
- Utilization rate: 77%, up from 74% in the second quarter
- EBITDA margin (profit before tax, interest, and depreciation as a share of net revenue): 29.4%, up 1.1 percentage points from a year ago
- Staff pay and benefits: 58.8% of net revenue, down 5.2 percentage points from a year ago by our math (or down 0.2 points after removing a deferred-compensation accounting offset in miscellaneous income)
- General and administrative overhead: 4.8% of net revenue, down 0.8 percentage points by our math
The jump to 77% utilization matters because the second quarter's 74% rate had been flattered by the single large study. Beating the forecast by two points as that study stepped down shows strong underlying demand across the firm's 950-plus consultants, which drove the full-year margin outlook raise.
What to watch: fourth-quarter utilization on the conference call. A forecast above 68% would show that busyness is holding up into the seasonally slower holiday period.
Cash Rebounded by $48 Million as Buybacks Paused
Exponent spent $146.1 million buying back its own stock in the first half of the year, which drew its cash balance down from $221.9 million to $66.6 million. That left cash near the bottom of the $50 million to $70 million operating range management likes to keep, while first-half cash flow fell behind earnings because client bills went unpaid.
In the third quarter, the consulting group paused share repurchases entirely, keeping year-to-date buybacks at $146.1 million, and paid $14.8 million in dividends by our math. Cash on the balance sheet rose by $48.1 million to $114.7 million, and unpaid client bills started to come in. The firm also declared its regular $0.31 quarterly dividend.
Following through on last quarter's plan to slow buybacks and collecting on client bills rebuilt the cash buffer in a single quarter. The firm now sits well above its target cash floor with zero debt, which supports management's earlier forecast for over $100 million of second-half free cash flow.
What to watch: operating cash flow in the third-quarter filing. A nine-month total above $90 million would confirm that third-quarter cash collections put the second-half cash goal within reach.
🐻 Bear Case
Environmental and Health Growth Slowed Back to 3%
Exponent's smaller division, environmental and health, makes up 15% of revenue before reimbursements and advises clients on chemical regulations and safety. After shrinking 5% in last year's fourth quarter and growing 2% in the first quarter, the unit bounced back to 9% growth in the second quarter.
That rebound did not last. Third-quarter revenue before reimbursements in the segment rose just 3% from a year ago, bringing nine-month growth to 4%. The company said growth came from projects "assessing the effects of chemicals on human health and the environment".
Because the environmental division keeps lagging the 13% pace of the engineering practice, the company relies entirely on one half of its portfolio for double-digit growth.
What to watch: environmental and health revenue growth in the fourth quarter, when it faces an easier comparison against last year's 5% decline. Growth below 5% on that easy base would show the practice is stuck in low gear.
Pass-Through Costs Still Inflate Headline Revenue Growth
Exponent leads its results section with total revenues up 18% to $173.7 million, alongside revenue before reimbursements up 11.7% (reported as 12%) to $153.1 million. The gap between the two numbers is reimbursable expenses — outside costs like study participant fees and subcontractors that the firm bills directly to clients at zero profit.
Those pass-through costs more than doubled from a year ago to $20.7 million, making up 11.9% of total revenue compared with 6.8% last year by our math. While total revenue grew 18.1%, net income rose only 10.3% to $30.9 million, partly because interest income fell by $1.6 million after first-half buybacks reduced cash.
The 18% headline rate overstates how fast the fee-earning business is growing, and the heavy pass-through mix will also dilute the engineering segment's reported operating margin in the quarterly filing.
What to watch: subcontractor fees and segment operating profit in the quarterly filing. That table will show whether underlying segment margins expanded once pass-through costs are stripped out.
Risks This Quarter Didn't Answer
Several standing concerns about staffing capacity, pricing power, and artificial intelligence cannot be read from the earnings release alone and await the conference call or quarterly filing.
- Consultant headcount and hiring: no technical full-time employee growth rate was printed to test whether tight PhD supply is capping capacity (guided 4% to 5% on last quarter's call).
- Pricing power: no realized billing rate increase was printed in the release (guided 3% to 4% for the quarter and 3.5% to 4% for the year).
- Large study and client share: the release did not state whether the single large study ran at the expected 2% of net revenue, or whether the 11% client stayed above 10%.
- AI displacement debate: Corrigan noted work "validating AI-enabled systems", but testing whether analysts still question AI replacing basic consulting work requires the call Q&A.
💲 Other KPIs
Up 43.4% from $12.9 million a year ago by our math, though down $3.5 million from the second quarter's $22.0 million peak. Current deferred revenue is cash clients pay in advance for consulting work not yet performed. Staying well above last year's level indicates healthy upfront client commitments entering the fourth quarter.
Unpaid client bills fell 4.1% from $218.5 million in the second quarter, though they remain up 15.2% from a year ago by our math against 11.7% net revenue growth. The sequential drop after a 20% first-half build released cash back onto the balance sheet during the third quarter.
Down 5.4% from 51.2 million shares a year ago by our math, following $146.1 million of first-half stock buybacks. The lower share count turned a 10.3% rise in third-quarter net income into a 16.4% increase in diluted earnings per share, to $0.64.
🔮 Guidance
Raised. The middle of the full-year outlook moved up 1 percentage point to 10.5% growth. By our math, that full-year midpoint leaves 7.7% growth for the fourth quarter, even below the separate fourth-quarter outlook. It is the second raise this year: +0.0 points in the first quarter, +1.5 points in the second, and +1.0 point today.
New. The plan calls for 9% growth at the middle of the range, down from 11.7% in the third quarter and 7.9% lower sequentially in dollar terms by our math. Exponent has beaten its quarterly net revenue growth midpoint for four straight quarters by an average of 2.8 percentage points; if the pattern holds, fourth-quarter growth would land near 11.8% by our math.
Raised. Management lifted the full-year profit margin range by 0.2 percentage points to a 28.15% midpoint. Because the first three quarters already ran at 28.8%, the full-year midpoint implies a 25.9% margin in the fourth quarter by our math, below the explicit fourth-quarter margin forecast. Second raise this year: +0.0 points, +0.1 points, +0.2 points.
New. The fourth-quarter plan has profit margins stepping down to 26.55% at the middle of the range from 29.4% in the third quarter, reflecting seasonal holiday time off. That midpoint sits 0.25 percentage points below the 26.8% margin recorded in the fourth quarter of last year.
❓ Key Questions
How much did the largest client and study contribute?
One client made up 11% of second-quarter revenue and one user research study was 4% of net revenue before an expected drop to 2%. Knowing both figures for the third quarter will show how much other clients drove the 12% net revenue growth.
What were consultant headcount growth and billing rate increases?
Management previously forecast 4% to 5% technical staff growth and 3% to 4% higher billing rates for the third quarter. Without those numbers in the release, investors cannot see how much of the revenue beat came from hiring versus utilization.
How fast did proactive work grow versus reactive dispute work?
Chief executive Catherine Corrigan said both user research and dispute work grew in the quarter, but the firm has not given the numerical split this year. That split would show how fast the proactive product-testing business is scaling.
Why does the full-year outlook imply a slower fourth quarter?
By our math, the 10.5% full-year net revenue growth midpoint implies 7.7% growth in the fourth quarter, below the 9% fourth-quarter outlook midpoint. Management should clarify whether the full-year range is simply rounding or builds in extra year-end caution.